Checkpoint Therapeutics Q1 2023 Earnings Report
Key Takeaways
Checkpoint Therapeutics announced the FDA accepted the BLA filing for cosibelimab in March and is preparing for a potential commercial launch in 2024. The company is also progressing active discussions with third parties to evaluate potential partnerships and other corporate development transactions.
FDA accepted the BLA filing for cosibelimab for metastatic or locally advanced cutaneous squamous cell carcinoma.
PDUFA goal date of January 3, 2024, was set for cosibelimab.
Checkpoint is preparing for a potential commercial launch in 2024.
Active discussions are ongoing with multiple third parties regarding potential partnerships and other corporate development transactions.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
The press release contains forward-looking statements regarding the FDA review of the BLA for cosibelimab, the commercial potential of cosibelimab if approved, and projections of publication and regulatory review timelines.